financetom
Business
financetom
/
Business
/
E.l.f. Beauty Expected to Meet Fiscal Q1 Sales Forecasts, Oppenheimer Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
E.l.f. Beauty Expected to Meet Fiscal Q1 Sales Forecasts, Oppenheimer Says
Aug 4, 2025 8:36 AM

11:11 AM EDT, 08/04/2025 (MT Newswires) -- E.l.f. Beauty's (ELF) fiscal Q1 sales and adjusted earnings before interest, taxes, depreciation and amortization are expected to meet market expectations, helped by recent strength in the overall beauty sector, Oppenheimer said in a note Monday.

Wall Street expectations of 9.4% sales growth and adjusted EBITDA of $74 million seem achievable and "could lend to upside," the analysts said.

Oppenheimer analysts also said that investor interest in the cosmetics company has increased, largely driven by enthusiasm surrounding the acquisition of Rhode, and to a lesser extent, expectations that price increases across E.l.f.'s product portfolio could help accelerate revenue growth.

The analysts said the primary focus for them and their investor conversations is the company's upcoming financial guidance. At the very least, the analysts said they expect management to provide guidance for fiscal Q2 and to offer more detailed financial disclosures related to the Rhode acquisition. The analysts said they hope to hear about Rhode's growth trajectory in recent months and what management expects for the remainder of the fiscal year.

E.l.f. Beauty is scheduled to report fiscal Q1 results after the close on Wednesday.

Oppenheimer has a perform rating on the stock.

Price: 115.00, Change: -1.42, Percent Change: -1.22

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Satellos Bioscience Completes Enrollment of All Dose Cohorts for Phase 1 SAT-3247 Trial
Satellos Bioscience Completes Enrollment of All Dose Cohorts for Phase 1 SAT-3247 Trial
Feb 10, 2025
08:17 AM EST, 02/10/2025 (MT Newswires) -- Satellos Bioscience ( MSCLF ) on Monday said it has completed enrollment of all four multiple-ascending dose cohorts for the Phase 1 clinical trial of SAT-3247 in healthy volunteers. SAT-3247 is a small molecule drug being developed by Satellos to regenerate skeletal muscle which is lost in Duchenne muscular dystrophy (DMD) and other...
Hain Celestial Explores Strategic Options for Personal Care Business
Hain Celestial Explores Strategic Options for Personal Care Business
Feb 10, 2025
08:18 AM EST, 02/10/2025 (MT Newswires) -- Hain Celestial Group ( HAIN ) said Monday it is exploring strategic options for its personal care business as it shifts focus to its better-for-you food and beverages portfolio. The company reported a 38% year-over-year decline in organic net sales for its personal care business for its fiscal Q2 ended Dec. 31. HAIN...
BRIEF-NXP Agrees To Acquire Edge AI Pioneer Kinara
BRIEF-NXP Agrees To Acquire Edge AI Pioneer Kinara
Feb 10, 2025
Feb 10 (Reuters) - NXP Semiconductors ( NXPI ): * NXP AGREES TO ACQUIRE EDGE AI PIONEER KINARA TO REDEFINE THE INTELLIGENT EDGE * NXP SEMICONDUCTORS NV ( NXPI ) - DEAL VALUED AT $307 MILLION, EXPECTED TO CLOSE IN H1 2025 Source text: Further company coverage: ...
GoldHaven Says Copecal Gold Project in Brazil Holds 'Strong Potential' for Gold Mineralization
GoldHaven Says Copecal Gold Project in Brazil Holds 'Strong Potential' for Gold Mineralization
Feb 10, 2025
08:16 AM EST, 02/10/2025 (MT Newswires) -- GoldHaven Resources ( GHVNF ) on Monday said its 100%-owned Copecal Gold Project in Brazil holds strong potential for gold mineralization as it has a solid foundation of historic exploration data, favorable geological setting, and a systematic exploration strategy. Exploration work conducted by AngloGold Ashanti from 2010 to 2016 had uncovered multiple gold-bearing...
Copyright 2023-2026 - www.financetom.com All Rights Reserved